Approval Letter Other 214927 (Jan 1, 2024)

Summary

The FDA issued a Complete Response letter for NDA 214927 for arimoclomol capsules, indicating that the application cannot be approved in its present form due to a lack of substantial evidence of effectiveness. Key concerns include issues with the 5-domain NPC Clinical Severity Scale (5DNPCCSS) as a primary endpoint, the statistical analysis (hypothetical estimand vs. while-on-treatment estimand), and weak/contradictory confirmatory evidence from in vitro and animal studies.

Key points

• Provide substantial evidence of effectiveness for arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
• Address concerns regarding the validity and reliability of the 5-domain NPC Clinical Severity Scale (5DNPCCSS) as a primary efficacy endpoint.
• Incorporate performance-based assessments to standardize the evaluation of specific domains (e.g., cognition, ambulation, fine motor, memory) within the NPCCSS.
• Demonstrate that the measurement of the domains of the NPCCSS are standardized across patients and sites.
• Provide evidence that the NPCCSS scoring is reliable and reproducible.
• Address the issues identified with the swallow domain of the 5DNPCCSS, ensuring it accurately reflects the patient's level of swallowing dysfunction and clinical progression.
• Address concerns regarding problematic response options in other 5DNPCCSS domains (e.g., ambulation, cognition, fine motor skills).
• Provide stronger and consistent confirmatory evidence of effectiveness, addressing the clinical relevance of in vitro findings and the contradictory results from animal studies.

Cited reasons

• Lack of Substantial Evidence of Effectiveness
• Validity and Statistical Concerns with 5DNPCCSS Primary Efficacy Endpoint
• Weak and Contradictory Confirmatory Evidence
• Inadequate Biomarker Data for Confirmatory Evidence
• The FDA issued a Complete Response Letter for arimoclomol capsules due to a lack of substantial evidence of effectiveness for the treatment of Neimann-Pick disease Type C (NPC). Key concerns include issues with the primary efficacy endpoint (5DNPCCSS) regarding its validity and statistical significance, as well as weak and contradictory confirmatory evidence from nonclinical, in vitro, and clinical pharmacology data, and inadequate biomarker data.

Recommended actions

• Provide substantial evidence of effectiveness for arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
• Address concerns regarding the validity and reliability of the 5-domain NPC Clinical Severity Scale (5DNPCCSS) as a primary efficacy endpoint.
• Incorporate performance-based assessments to standardize the evaluation of specific domains (e.g., cognition, ambulation, fine motor, memory) within the NPCCSS.
• Demonstrate that the measurement of the domains of the NPCCSS are standardized across patients and sites.
• Provide evidence that the NPCCSS scoring is reliable and reproducible.
• Address the issues identified with the swallow domain of the 5DNPCCSS, ensuring it accurately reflects the patient's level of swallowing dysfunction and clinical progression.
• Address concerns regarding problematic response options in other 5DNPCCSS domains (e.g., ambulation, cognition, fine motor skills).
• Provide stronger and consistent confirmatory evidence of effectiveness, addressing the clinical relevance of in vitro findings and the contradictory results from animal studies.

Deficiency summary

The FDA issued a Complete Response Letter for arimoclomol capsules due to a lack of substantial evidence of effectiveness for the treatment of Neimann-Pick disease Type C (NPC). Key concerns include issues with the primary efficacy endpoint (5DNPCCSS) regarding its validity and statistical significance, as well as weak and contradictory confirmatory evidence from nonclinical, in vitro, and clinical pharmacology data, and inadequate biomarker data.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

NDA 505(b)

Impact

Impact score

0.95

Estimated delay

730 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The primary theme is the insufficient demonstration of substantial evidence of effectiveness, stemming from fundamental issues with the primary clinical endpoint's validity and statistical interpretation, coupled with weak and contradictory supporting nonclinical and biomarker data.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 5%